Release Date: August 13, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Capricor Therapeutics Inc CAPR is actively working with the FDA to amend its BLA for deramiocel, focusing on the upper limb skeletal muscle indication, which was the primary endpoint of the HOPE-3 study and showed statistically significant results.
- The HOPE-3 trial results were published in The Lancet, a prestigious peer-reviewed journal, providing strong external validation of the efficacy data.
- The company has a robust safety database, with over 1,300 infusions administered to more than 200 DMD patients, including some treated for over five years, demonstrating a well-characterized long-term safety profile.
- Capricor Therapeutics Inc (CAPR) maintains a strong cash position of approximately $237.9 million, providing financial flexibility to support ongoing regulatory and manufacturing activities.
- The company's in-house GMP manufacturing facility is operational and positioned to support an initial commercial launch, with expansion plans on track for 2027.
- The FDA has shown flexibility and willingness to review the proposed BLA amendment, indicating a collaborative approach to finding a path forward for deramiocel.
Negative Points
- The FDA's Advisory Committee voted 9 to 3 against the effectiveness of deramiocel for treating cardiomyopathy in DMD patients, a significant setback for the original indication.
- The statistical model for the key secondary endpoint (left ventricular ejection fraction) was revised, resulting in a less favorable p-value (0.09 vs. 0.04), which may raise concerns about data robustness.
- The company's dispute with NS Pharma over the US pricing agreement remains unresolved, with arbitration not expected to begin until fall, creating ongoing legal and commercial uncertainty.
- All pipeline programs not directly related to deramiocel are on hold, limiting diversification and future growth opportunities until regulatory clarity is achieved.
- The company reported a net loss of $40.7 million for Q2 2026, an increase from $25.9 million in the prior year, reflecting rising operating expenses and no revenue.
- The BLA review process has been extended due to the amendment, delaying the potential approval and commercial launch of deramiocel.
Q & A Highlights
Q: What was the outcome of the FDA's Advisory Committee meeting regarding deramiocel, and what is the company's next step?
A: Linda Marban, CEO, reported that the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 3 in favor and 9 against on whether the available evidence provides substantial evidence of effectiveness for deramiocel in treating cardiomyopathy in DMD patients. Despite this disappointment, the company is working with the FDA on a potential path forward focused on an upper limb skeletal muscle indication, which was the primary endpoint of the HOPE-3 study. They plan to submit an amendment to the BLA including 24-month open-label extension data and additional analyses, with the FDA indicating willingness to review and extend the PDUFA date accordingly.
Q: How did the statistical model change for the HOPE-3 trial's key secondary endpoint, and what was the impact?
A: Linda Marban, CEO, explained that an issue with the statistical model in the clinical study report was identified during peer review with The Lancet and the FDA. The company reverted to the pre-specified statistical analysis plan version 3.0, which included an interaction term for age and baseline. This change only impacted the left ventricular ejection fraction endpoint in all patients, shifting the treatment difference from 2.4 percentage points (p=0.04) to 1.8 percentage points (p=0.09). The pre-specified cardiomyopathy subgroup result remained unchanged at p=0.02 with a 2.8 percentage point treatment difference. The primary endpoint was unaffected and remains statistically significant.
Q: What is the status of the company's dispute with NS Pharma?
A: Linda Marban, CEO, stated that the company withdrew its motion for a preliminary injunction without prejudice, choosing to resolve the contractual dispute in arbitration following the FDA's decision to have a more complete regulatory record. The arbitration process is estimated to begin this fall. The company's position remains unchanged, believing the US pricing structure is fundamentally flawed and impedes patient access, and they continue to seek rescission of the agreement.
Q: What were the key financial results for the second quarter of 2026?
A: CFO Anthony Bergmann reported that as of June 30, 2026, the company had approximately $237.9 million in cash, cash equivalents, and marketable securities. Total operating expenses for Q2 2026 were approximately $42.9 million, up from $27.7 million in Q2 2025, driven by investments in clinical, regulatory, manufacturing, and commercial infrastructure. The net loss for Q2 2026 was approximately $40.7 million, or $0.70 per share, compared to a net loss of $25.9 million, or $0.57 per share, in Q2 2025.
Q: What is the status of the company's manufacturing and commercial readiness activities?
A: Linda Marban, CEO, noted that commercial readiness activities are continuing but at a slower pace until regulatory clarity is achieved. The in-house GMP manufacturing facility in San Diego is operational and positioned to support an initial commercial launch. The expansion to the second floor continues, with a goal of full validation and FDA approval estimated in 2027. Michael Moore has joined as Chief Commercial Officer to build out the launch organization.
Q: What is the company's plan for its pipeline programs outside of deramiocel?
A: Linda Marban, CEO, stated that all pipeline work not directly related to deramiocel is on hold until further regulatory clarity. Life cycle management for deramiocel, including regulatory engagement in Europe and Japan, has been initiated. Expansion plans for younger DMD patients and Becker muscular dystrophy remain priorities, but the timing of clinical trial initiations will be stage-gated by the US regulatory pathway timeline.
Q: What was the outcome of the FDA's bioresearch monitoring (BIMO) inspection?
A: Linda Marban, CEO, reported that the FDA conducted a BIMO inspection in July and issued a Form 483 citing one observation. The company has submitted its responses and is currently awaiting feedback from the agency.
Q: What is the significance of the HOPE-3 trial publication in The Lancet?
A: Linda Marban, CEO, highlighted that the full Phase 3 dataset was published in The Lancet following extensive independent peer review. The publication highlights the efficacy of deramiocel and includes the mechanism of action and individual patient-level data. The company believes this highly regarded publication will help support continued progress for the deramiocel program.
Q: What is the company's cash runway and how are they managing expenses?
A: CFO Anthony Bergmann noted that the company is pacing certain commercial expenditures as the regulatory timeline develops. The expense profile reflects investment across regulatory and clinical activities, manufacturing capacity expansion, and commercial readiness. The company continues to have flexibility in how it deploys capital across the remainder of the year.
Q: Why did the company decide not to hold a Q&A session on this call?
A: Linda Marban, CEO, explained that due to the sensitivity of ongoing discussions with the FDA, the company is not holding a Q&A session today. They look forward to providing updates as they become available.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
